Startups
MinervaX
https://minervax.comDeveloper of prophylactic vaccine against Group B Streptococcus.
Summary
Industry
Insights
MinervaX, based in Copenhagen, is advancing the biotech field by developing a prophylactic vaccine against Group B Streptococcus (GBS) infections. This focus positions it as a key player in prenatal health, addressing risks of neonatal infections currently managed through screening and antibiotics. By prioritizing vaccine development, MinervaX aims to offer a more effective and less intrusive solution. The company's B2B model, along with backing from investors like EQT Partners and Novo A/S, showcases its potential for medical advancement and commercial success. If successful, MinervaX could revolutionize prenatal care, leading to widespread adoption and significant market impact.
Total Funding
$176M
- 2023 Series C $57.3M
- 2022 Debt Financing $53.3M
- 2020 Series B $58.0M
- 2019 Unknown $5.0M
- 2014 Seed $3.1M
Investors
- Pureos Bioventures Series C
- EQT Partners Series C
- OrbiMed Series C
- European Investment Bank Debt Financing
- Industrifonden Series B
- Wellington Partners Series B
- Novo A/S Seed
- Vaekstfonden Seed
- Sunstone Life Science Ventures Seed